{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T07:13:49Z","timestamp":1778742829640,"version":"3.51.4"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:00:00Z","timestamp":1778716800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:00:00Z","timestamp":1778716800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Ophthalmol"],"DOI":"10.1007\/s10792-026-04100-z","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T07:05:02Z","timestamp":1778742302000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of netarsudil compared with prostaglandin-based therapies: a Bayesian network meta-analysis"],"prefix":"10.1007","volume":"46","author":[{"given":"Jun","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meiling","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaodan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,5,14]]},"reference":[{"issue":"10414","key":"4100_CR1","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1016\/s0140-6736(23)01289-8","volume":"402","author":"H Jayaram","year":"2023","unstructured":"Jayaram H, Kolko M, Friedman DS, Gazzard G (2023) Glaucoma: now and beyond. Lancet (London, England) 402(10414):1788\u20131801. https:\/\/doi.org\/10.1016\/s0140-6736(23)01289-8","journal-title":"Lancet (London, England)"},{"key":"4100_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12061225","author":"M Ayala","year":"2024","unstructured":"Ayala M (2024) Adding genetics to the risk factors model improved accuracy for detecting visual field progression in newly diagnosed exfoliation glaucoma patients. Biomedicines. https:\/\/doi.org\/10.3390\/biomedicines12061225","journal-title":"Biomedicines"},{"key":"4100_CR3","doi-asserted-by":"publisher","unstructured":"GBD 2019 Blindness and Vision Impairment Collaborators VLEGotGBoDS (2021) Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: the Right to Sight: an analysis for the Global Burden of Disease Study. The Lancet Global health. 9(2). pp e144-e60. https:\/\/doi.org\/10.1016\/s2214-109x(20)30489-7.","DOI":"10.1016\/s2214-109x(20)30489-7"},{"issue":"43","key":"4100_CR4","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000040306","volume":"103","author":"M Wu","year":"2024","unstructured":"Wu M, Zheng K, Cao Y, Wang J, Yin Q, Li T et al (2024) Asthma and eye diseases in middle-aged and elderly Chinese: A comprehensive analysis of CHARLS data. Medicine 103(43):e40306. https:\/\/doi.org\/10.1097\/md.0000000000040306","journal-title":"Medicine"},{"key":"4100_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/s12886-025-04104-w","author":"Y Zhen","year":"2025","unstructured":"Zhen Y, Mengfan W, YuFei T, Zihan H, Mingmin Y, Xiaohua P et al (2025) Efficacy analysis of microinvasive glaucoma surgery alone or in combination with phacoemulsification in patients with normal tension glaucoma: a systematic review and meta-analysis. BMC Ophthalmol. https:\/\/doi.org\/10.1186\/s12886-025-04104-w","journal-title":"BMC Ophthalmol"},{"key":"4100_CR6","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-023-01973-7","author":"PB John","year":"2023","unstructured":"John PB, Steven R Jr, Robert EA, Long VD, Angela CK, Dale WU et al (2023) Efficacy and safety of the travoprost intraocular implant in reducing topical IOP-lowering medication burden in patients with open-angle glaucoma or ocular hypertension. Drugs. https:\/\/doi.org\/10.1007\/s40265-023-01973-7","journal-title":"Drugs"},{"key":"4100_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11102696","author":"D Rong","year":"2022","unstructured":"Rong D, Chen X, Jingjiang X, Jianping H, Huaizhou W, Ningli W et al (2022) Pulsatile trabecular meshwork motion: an indicator of intraocular pressure control in primary open-angle glaucoma. J Clin Med. https:\/\/doi.org\/10.3390\/jcm11102696","journal-title":"J Clin Med"},{"key":"4100_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajoc.2025.102311","author":"A Soufiane","year":"2025","unstructured":"Soufiane A, Joana K, Scott Cn O, Malik YK, Cara ECY (2025) Netarsudil-associated conjunctival pigmentation. Am J Ophthalmol Case Rep. https:\/\/doi.org\/10.1016\/j.ajoc.2025.102311","journal-title":"Am J Ophthalmol Case Rep."},{"issue":"2","key":"4100_CR9","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1002\/jrsm.1037","volume":"3","author":"G Salanti","year":"2012","unstructured":"Salanti G (2012) Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool. Res Synth Methods 3(2):80\u201397. https:\/\/doi.org\/10.1002\/jrsm.1037","journal-title":"Res Synth Methods"},{"issue":"2","key":"4100_CR10","doi-asserted-by":"publisher","first-page":"130","DOI":"10.7326\/0003-4819-159-2-201307160-00008","volume":"159","author":"A Cipriani","year":"2013","unstructured":"Cipriani A, Higgins JP, Geddes JR, Salanti G (2013) Conceptual and technical challenges in network meta-analysis. Ann Intern Med 159(2):130\u2013137. https:\/\/doi.org\/10.7326\/0003-4819-159-2-201307160-00008","journal-title":"Ann Intern Med"},{"issue":"3","key":"4100_CR11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003583","volume":"18","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al (2021) The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. PLoS Med 18(3):e1003583. https:\/\/doi.org\/10.1371\/journal.pmed.1003583","journal-title":"PLoS Med"},{"key":"4100_CR12","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JP Higgins","year":"2011","unstructured":"Higgins JP, Altman DG, G\u00f8tzsche PC, J\u00fcni P, Moher D, Oxman AD et al (2011) The Cochrane collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ (Clinical Res) 343:d5928. https:\/\/doi.org\/10.1136\/bmj.d5928","journal-title":"BMJ (Clinical Res)"},{"issue":"7\u20138","key":"4100_CR13","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1002\/sim.3767","volume":"29","author":"S Dias","year":"2010","unstructured":"Dias S, Welton NJ, Caldwell DM, Ades AE (2010) Checking consistency in mixed treatment comparison meta-analysis. Stat Med 29(7\u20138):932\u2013944. https:\/\/doi.org\/10.1002\/sim.3767","journal-title":"Stat Med"},{"issue":"2","key":"4100_CR14","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1001\/archopht.123.2.186","volume":"123","author":"ES Arcieri","year":"2005","unstructured":"Arcieri ES, Santana A, Rocha FN, Guapo GL, Costa VP (2005) Blood-aqueous barrier changes after the use of prostaglandin analogues in patients with pseudophakia and aphakia: a 6-month randomized trial. Arch Ophthalmol 123(2):186\u2013192. https:\/\/doi.org\/10.1001\/archopht.123.2.186","journal-title":"Arch Ophthalmol"},{"key":"4100_CR15","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.ajo.2019.06.016","volume":"207","author":"S Asrani","year":"2019","unstructured":"Asrani S, Robin AL, Serle JB, Lewis RA, Usner DW, Kopczynski CC et al (2019) Netarsudil\/Latanoprost fixed-dose combination for elevated intraocular pressure: three-month data from a randomized phase 3 trial. Am J Ophthalmol 207:248\u2013257. https:\/\/doi.org\/10.1016\/j.ajo.2019.06.016","journal-title":"Am J Ophthalmol"},{"issue":"7","key":"4100_CR16","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1097\/IJG.0b013e3181c4aeac","volume":"19","author":"CM Birt","year":"2010","unstructured":"Birt CM, Buys YM, Ahmed II, Trope GE (2010) Prostaglandin efficacy and safety study undertaken by race (the PRESSURE study). J Glaucoma 19(7):460\u2013467. https:\/\/doi.org\/10.1097\/IJG.0b013e3181c4aeac","journal-title":"J Glaucoma"},{"issue":"11","key":"4100_CR17","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1136\/bjo.2006.094326","volume":"90","author":"LB Cantor","year":"2006","unstructured":"Cantor LB, Hoop J, Morgan L, Wudunn D, Catoira Y (2006) Intraocular pressure-lowering efficacy of bimatoprost 0.03% and travoprost 0.004% in patients with glaucoma or ocular hypertension. The British J Ophthalmol 90(11):1370. https:\/\/doi.org\/10.1136\/bjo.2006.094326","journal-title":"The British J Ophthalmol"},{"issue":"7","key":"4100_CR18","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/s0011-393x(03)00112-7","volume":"64","author":"N Cardascia","year":"2003","unstructured":"Cardascia N, Vetrugno M, Trabucco T, Cantatore F, Sborgia C (2003) Effects of travoprost eye drops on intraocular pressure and pulsatile ocular blood flow: a 180-day, randomized, double-masked comparison with latanoprost eye drops in patients with open-angle glaucoma. Curr Ther Res Clin Exp 64(7):389\u2013400. https:\/\/doi.org\/10.1016\/s0011-393x(03)00112-7","journal-title":"Curr Ther Res Clin Exp"},{"issue":"5","key":"4100_CR19","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1159\/000079472","volume":"218","author":"M Cellini","year":"2004","unstructured":"Cellini M, Caramazza R, Bonsanto D, Bernabini B, Campos EC (2004) Prostaglandin analogs and blood-aqueous barrier integrity: a flare cell meter study. Ophthalmologica 218(5):312\u2013317. https:\/\/doi.org\/10.1159\/000079472","journal-title":"Ophthalmologica"},{"issue":"3","key":"4100_CR20","first-page":"39","volume":"49","author":"D Chiseli\u0163\u0103","year":"2005","unstructured":"Chiseli\u0163\u0103 D, Antohi I, Medvichi R, Danielescu C (2005) Comparative analysis of the efficacy and safety of latanoprost, travoprost and the fixed combination timolol-dorzolamide; a prospective, randomized, masked, cross-over design study. Oftalmologia 49(3):39\u201345","journal-title":"Oftalmologia"},{"issue":"7","key":"4100_CR21","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1111\/j.1442-9071.2010.02305.x","volume":"38","author":"UA Faridi","year":"2010","unstructured":"Faridi UA, Saleh TA, Ewings P, Venkateswaran M, Cadman DH, Samarasinghe RA et al (2010) Comparative study of three prostaglandin analogues in the treatment of newly diagnosed cases of ocular hypertension, open-angle and normal tension glaucoma. Clin Exp Ophthalmol 38(7):678\u2013682. https:\/\/doi.org\/10.1111\/j.1442-9071.2010.02305.x","journal-title":"Clin Exp Ophthalmol"},{"issue":"4","key":"4100_CR22","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1007\/s12325-015-0205-5","volume":"32","author":"P Fogagnolo","year":"2015","unstructured":"Fogagnolo P, Dipinto A, Vanzulli E, Maggiolo E, De Cilla S, Autelitano A et al (2015) A 1-year randomized study of the clinical and confocal effects of tafluprost and latanoprost in newly diagnosed glaucoma patients. Adv Ther 32(4):356\u2013369. https:\/\/doi.org\/10.1007\/s12325-015-0205-5","journal-title":"Adv Ther"},{"issue":"3","key":"4100_CR23","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1007\/BF02850299","volume":"18","author":"S Gandolfi","year":"2001","unstructured":"Gandolfi S, Simmons ST, Sturm R, Chen K, VanDenburgh AM (2001) Three-month comparison of bimatoprost and latanoprost in patients with glaucoma and ocular hypertension. Adv Ther 18(3):110\u2013121. https:\/\/doi.org\/10.1007\/BF02850299","journal-title":"Adv Ther"},{"issue":"4","key":"4100_CR24","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/sj.eye.6702243","volume":"21","author":"IF Hepsen","year":"2007","unstructured":"Hepsen IF, Ozkaya E (2007) 24-h IOP control with latanoprost, travoprost, and bimatoprost in subjects with exfoliation syndrome and ocular hypertension. Eye (Lond) 21(4):453\u2013458. https:\/\/doi.org\/10.1038\/sj.eye.6702243","journal-title":"Eye (Lond)"},{"key":"4100_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/ph14060501","author":"JM Kim","year":"2021","unstructured":"Kim JM, Park SW, Seong M, Ha SJ, Lee JW, Rho S et al (2021) Comparison of the Safety and Efficacy between Preserved and Preservative-Free Latanoprost and Preservative-Free Tafluprost. Pharmaceuticals (Basel). https:\/\/doi.org\/10.3390\/ph14060501","journal-title":"Pharmaceuticals (Basel)"},{"issue":"6","key":"4100_CR26","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1136\/bjo.2006.106690","volume":"91","author":"AG Konstas","year":"2007","unstructured":"Konstas AG, Holl\u00f3 G, Irkec M, Tsironi S, Durukan I, Goldenfeld M et al (2007) Diurnal IOP control with bimatoprost versus latanoprost in exfoliative glaucoma: a crossover, observer-masked, three-centre study. Br J Ophthalmol 91(6):757\u2013760. https:\/\/doi.org\/10.1136\/bjo.2006.106690","journal-title":"Br J Ophthalmol"},{"key":"4100_CR27","doi-asserted-by":"publisher","DOI":"10.1177\/11206721211006573","author":"S Lemmens","year":"2021","unstructured":"Lemmens S, Rossetti L, Oddone F, Sunaric-M\u00e9gevand G, Hommer A, Vandewalle E et al (2021) Comparison of preserved bimatoprost 001% with preservative-free tafluprost: A randomised, investigator-masked, 3-month crossover, multicentre trial SPORT II. Eur J Ophthalmol. https:\/\/doi.org\/10.1177\/11206721211006573","journal-title":"Eur J Ophthalmol"},{"issue":"5","key":"4100_CR28","doi-asserted-by":"publisher","first-page":"399","DOI":"10.3341\/kjo.2014.28.5.399","volume":"28","author":"D Mishra","year":"2014","unstructured":"Mishra D, Sinha BP, Kumar MS (2014) Comparing the efficacy of latanoprost (0.005%), bimatoprost (0.03%), travoprost (0.004%), and timolol (0.5%) in the treatment of primary open angle glaucoma. Korean J Ophthalmol 28(5):399\u2013407. https:\/\/doi.org\/10.3341\/kjo.2014.28.5.399","journal-title":"Korean J Ophthalmol"},{"issue":"11","key":"4100_CR29","doi-asserted-by":"publisher","first-page":"3825","DOI":"10.1007\/s10792-021-01947-2","volume":"41","author":"OE Muz","year":"2021","unstructured":"Muz OE, Dagdelen K, Pirdal T, Guler M (2021) Comparison of BAK-preserved latanoprost and polyquad-preserved travoprost on ocular surface parameters in patients with glaucoma and ocular hypertension. Int Ophthalmol 41(11):3825\u20133835. https:\/\/doi.org\/10.1007\/s10792-021-01947-2","journal-title":"Int Ophthalmol"},{"key":"4100_CR30","unstructured":"US National Library of Medicine (2011) Safety and efficacy of bimatoprost compared with latanoprost in patients with glaucoma or ocular hypertension. ClinicalTrials.gov, https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00541242"},{"issue":"4","key":"4100_CR31","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/s0002-9394(01)01177-1","volume":"132","author":"PA Netland","year":"2001","unstructured":"Netland PA, Landry T, Sullivan EK, Andrew R, Silver L, Weiner A et al (2001) Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am J Ophthalmol 132(4):472\u2013484. https:\/\/doi.org\/10.1016\/s0002-9394(01)01177-1","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"4100_CR32","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/bf02850259","volume":"20","author":"RJ Noecker","year":"2003","unstructured":"Noecker RJ, Earl ML, Mundorf T, Peace J, Williams RD (2003) Bimatoprost 0.03% versus travoprost 0.004% in black Americans with glaucoma or ocular hypertension. Adv Ther 20(2):121\u2013128. https:\/\/doi.org\/10.1007\/bf02850259","journal-title":"Adv Ther"},{"issue":"10","key":"4100_CR33","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1089\/jop.2014.0122","volume":"31","author":"SH Park","year":"2015","unstructured":"Park SH, Yoo SH, Ha SJ (2015) Comparison of ocular pulse amplitude-lowering effects of Tafluprost and Latanoprost by Dynamic Contour Tonometry. J Ocul Pharmacol Ther 31(10):617\u2013622. https:\/\/doi.org\/10.1089\/jop.2014.0122","journal-title":"J Ocul Pharmacol Ther"},{"issue":"1","key":"4100_CR34","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1177\/112067210601600113","volume":"16","author":"S Parmaksiz","year":"2006","unstructured":"Parmaksiz S, Y\u00fcksel N, Karabas VL, Ozkan B, Demirci G, Caglar Y (2006) A comparison of travoprost, latanoprost, and the fixed combination of dorzolamide and timolol in patients with pseudoexfoliation glaucoma. Eur J Ophthalmol 16(1):73\u201380","journal-title":"Eur J Ophthalmol"},{"issue":"5","key":"4100_CR35","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1016\/s0002-9394(03)00098-9","volume":"135","author":"RK Parrish","year":"2003","unstructured":"Parrish RK, Palmberg P, Sheu WP (2003) A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study. Am J Ophthalmol 135(5):688\u2013703. https:\/\/doi.org\/10.1016\/s0002-9394(03)00098-9","journal-title":"Am J Ophthalmol"},{"issue":"6","key":"4100_CR36","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1007\/s00417-016-3299-9","volume":"254","author":"I Stalmans","year":"2016","unstructured":"Stalmans I, Oddone F, Cordeiro MF, Hommer A, Montesano G, Ribeiro L et al (2016) Comparison of preservative-free latanoprost and preservative-free bimatoprost in a multicenter, randomized, investigator-masked cross-over clinical trial, the SPORT trial. Graefes Arch Clin Exp Ophthalmol 254(6):1151\u20131158. https:\/\/doi.org\/10.1007\/s00417-016-3299-9","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"2","key":"4100_CR37","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.ajo.2007.10.002","volume":"145","author":"R Varma","year":"2008","unstructured":"Varma R, Hwang LJ, Grunden JW, Bean GW (2008) Inter-visit intraocular pressure range: an alternative parameter for assessing intraocular pressure control in clinical trials. Am J Ophthalmol 145(2):336\u2013342. https:\/\/doi.org\/10.1016\/j.ajo.2007.10.002","journal-title":"Am J Ophthalmol"},{"issue":"5","key":"4100_CR38","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.ogla.2019.03.007","volume":"2","author":"TR Walters","year":"2019","unstructured":"Walters TR, Ahmed IIK, Lewis RA, Usner DW, Lopez J, Kopczynski CC et al (2019) Once-daily netarsudil\/latanoprost fixed-dose combination for elevated intraocular pressure in the randomized phase 3 MERCURY-2 study. Ophthalmology Glaucoma 2(5):280\u2013289. https:\/\/doi.org\/10.1016\/j.ogla.2019.03.007","journal-title":"Ophthalmology Glaucoma"},{"issue":"3","key":"4100_CR39","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1089\/jop.2009.0134","volume":"26","author":"JT Whitson","year":"2010","unstructured":"Whitson JT, Trattler WB, Matossian C, Williams J, Hollander DA (2010) Ocular surface tolerability of prostaglandin analogs in patients with glaucoma or ocular hypertension. J Ocul Pharmacol Ther 26(3):287\u2013292. https:\/\/doi.org\/10.1089\/jop.2009.0134","journal-title":"J Ocul Pharmacol Ther"},{"key":"4100_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2015.09.005","author":"L Tianjing","year":"2015","unstructured":"Tianjing L, Kristina L, Benjamin R, Hwanhee H, Qiyuan S, David SF et al (2015) Comparative effectiveness of first-line medications for primary open-angle glaucoma: a systematic review and network meta-analysis. Ophthalmology. https:\/\/doi.org\/10.1016\/j.ophtha.2015.09.005","journal-title":"Ophthalmology"},{"key":"4100_CR41","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-020-01277-2","author":"A Sanjay","year":"2020","unstructured":"Sanjay A, Jason B, Edward H, Hayley M, Huan S, Richard AL et al (2020) Fixed-dose combination of netarsudil and latanoprost in ocular hypertension and open-angle glaucoma: pooled efficacy\/safety analysis of Phase 3 MERCURY-1 and -2. Adv Ther. https:\/\/doi.org\/10.1007\/s12325-020-01277-2","journal-title":"Adv Ther"},{"key":"4100_CR42","doi-asserted-by":"publisher","DOI":"10.2147\/opth.S491636","author":"B Jason","year":"2025","unstructured":"Jason B, Ehsan S, Gagan S, Casey K, Mohinder MM (2025) Effects of switching to netarsudil\/latanoprost fixed dose combination from various latanoprost regimens: the Phase 4 MORE study. Clin Ophthalmol. https:\/\/doi.org\/10.2147\/opth.S491636","journal-title":"Clin Ophthalmol"},{"issue":"3","key":"4100_CR43","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1007\/s12325-020-01227-y","volume":"37","author":"CE Wisely","year":"2020","unstructured":"Wisely CE, Sheng H, Heah T, Kim T (2020) Effects of netarsudil and latanoprost alone and in fixed combination on corneal endothelium and corneal thickness: post-hoc analysis of MERCURY-2. Adv Ther 37(3):1114\u20131123. https:\/\/doi.org\/10.1007\/s12325-020-01227-y","journal-title":"Adv Ther"},{"key":"4100_CR44","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.60831","author":"G Li","year":"2021","unstructured":"Li G, Lee C, Read AT, Wang K, Ha J, Kuhn M et al (2021) Anti-fibrotic activity of a rho-kinase inhibitor restores outflow function and intraocular pressure homeostasis. Elife. https:\/\/doi.org\/10.7554\/eLife.60831","journal-title":"Elife"},{"key":"4100_CR45","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.ajo.2020.09.050","volume":"222","author":"MO Price","year":"2021","unstructured":"Price MO, Feng MT, Price FW Jr. (2021) Randomized, double-masked trial of netarsudil 0.02% ophthalmic solution for prevention of corticosteroid-induced ocular hypertension. Am J Ophthalmol 222:382\u2013387. https:\/\/doi.org\/10.1016\/j.ajo.2020.09.050","journal-title":"Am J Ophthalmol"},{"issue":"5","key":"4100_CR46","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.ogla.2020.05.008","volume":"3","author":"JW Brubaker","year":"2020","unstructured":"Brubaker JW, Teymoorian S, Lewis RA, Usner D, McKee HJ, Ramirez N et al (2020) One year of netarsudil and latanoprost fixed-dose combination for elevated intraocular pressure: phase 3, randomized MERCURY-1 study. Ophthalmol Glaucoma 3(5):327\u2013338. https:\/\/doi.org\/10.1016\/j.ogla.2020.05.008","journal-title":"Ophthalmol Glaucoma"}],"container-title":["International Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-026-04100-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10792-026-04100-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-026-04100-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T07:05:09Z","timestamp":1778742309000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10792-026-04100-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,14]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4100"],"URL":"https:\/\/doi.org\/10.1007\/s10792-026-04100-z","relation":{},"ISSN":["1573-2630"],"issn-type":[{"value":"1573-2630","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,14]]},"assertion":[{"value":"7 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"231"}}